[A Case Report of a Patient with Metastatic Adrenocortical Carcinoma who Received the Combination Etoposide, Doxorubicin, Cisplatin, and Mitotane Therapy and Achieved Remission]

Hinyokika Kiyo. 2022 May;68(5):139-143. doi: 10.14989/ActaUrolJap_68_5_139.
[Article in Japanese]

Abstract

A 40-year-old Japanese female was referred to our institution with a high serum lactate dehydrogenase level. Computed tomography (CT) showed a large right adrenal tumor, 14 cm in size without distant metastases. The patient was clinically diagnosed with T2N0M0 adrenocortical carcinoma and underwent right adrenalectomy. The pathological diagnosis was adrenocortical carcinoma with negative surgical margin. The patient was administered mitotane for 2 years as adjuvant therapy. Subsequently, CT revealed asynchronous multiple metastases, including liver, lung, left kidney, and right acetabulum. The patient received 15 courses of EDP (a combination of etoposide, doxorubicin, and cisplatin) plus mitotane therapy, and had stable disease without new lesions.

Publication types

  • Case Reports

MeSH terms

  • Adrenal Cortex Neoplasms* / diagnostic imaging
  • Adrenal Cortex Neoplasms* / drug therapy
  • Adrenal Cortex Neoplasms* / surgery
  • Adrenocortical Carcinoma* / diagnostic imaging
  • Adrenocortical Carcinoma* / drug therapy
  • Adrenocortical Carcinoma* / surgery
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cisplatin
  • Doxorubicin / therapeutic use
  • Etoposide / therapeutic use
  • Female
  • Humans
  • Mitotane / therapeutic use

Substances

  • Etoposide
  • Mitotane
  • Doxorubicin
  • Cisplatin